Chelation therapy, a treatment long undervalued by conventional medicine, has been used by alternative medicine practitioners to alleviate various metabolic toxicities. In particular, there has been significant controversy around its use in patients with coronary artery disease. We performed a focused review of the recent National Institute of Health (NIH) trial to investigate the role of chelation therapy in the treatment of patients with coronary artery disease. The study was the first randomized, factorial trial (n=1708) in patients with coronary artery disease, already receiving standard, guideline-approved treatment. Patients were randomized to EDTA chelation therapy with or without oral multivitamin multimineral supplement (OMVM). The trial showed that EDTA chelation reduced the primary endpoint (a composite of total mortality, recurrent myocardial infarction, stroke, coronary revascularization, or hospitalization for angina) by 18% overall (95% confidence interval [CI]: 1‐21%). This benefit was increased by addition of OMVM (26% relative reduction; 95% CI: 5‐23%), and the effect was most pronounced in patients with diabetes: 51% (95% CI: 25‐67%) relative reduction for chelation with, and 41% (95% CI: 21‐56%) without OMVM, respectively. Chelation therapy, recently evaluated in the NIH trial of patients with coronary artery disease, has been given a class IIb (may be beneficial) designation by the American College of Cardiology Chronic Ischemic Heart Disease Guidelines. The positive and significant impact of chelation therapy on morbidity and mortality of patients already receiving standard contemporary treatment is pivotal to the advancement of chelation therapy into the mainstream of coronary artery disease treatments.
Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014; 64(18):1929–1949.
Lamas GA, Boineau R, Goertz C, et al. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: the factorial group results of the Trial to Assess Chelation Therapy. Am Heart J. 2014; 168(1):37–44.
Boyle AJ, Clarke NE, Mosher RE, et al. Chelation therapy in circulatory and sclerosing diseases. Fed Proc. 1961; 20(3)Pt 2:243–252.
Kitchell JR, Meltzer LE, Seven MJ. Potential uses of chelation methods in the treatment of cardiovascular diseases. Prog Cardiovasc Dis. 1961; 3:338–349.
Lamar CP. Chelation endarterectomy for occlusive atherosclerosis. J Am Geriatr Soc. 1966; 14(3):272–294.
Lamar CP. Chelation therapy of occlusive arteriosclerosis in diabetic patients. Angiology. 1964; 15:379–395.
Casdorph HR. Chelation therapy: a reappraisal. NZ Med J. 1983; 96(724):66–67.
Chelation therapy ineffective as atherosclerosis treatment. Mayo Clin Health Lett. 2002; 20(6):4.
Can chelation therapy cure heart disease? Johns Hopkins Med Lett Health After 50. 1998; 10(4):8.
Diagnostic and therapeutic technology assessment. Chelation therapy. J Am Med Assoc. 1983; 250(5):672.
Fowles RE. Myocardial infarction in the 1990s. The importance of early thrombolytic therapy. Postgrad Med. 1995; 97(5):135–138, 141–142, 145–146.
Kaski JC. High dose statin treatment and new onset diabetes. Cardiovasc Drugs Ther. 2011; 25(6):571–572.
Hu M, Cheung BM, Tomlinson B. Safety of statins: an update. Ther Adv Drug Saf. 2012; 3(3):133–144.
Rosenberg K. New AHA-ACC guidelines could lead to major changes in clinical practice. Am J Nurs. 2014; 114(2):13.
Klose G, Beil FU, Dieplinger H, et al. New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. Wien Klin Wochenschr. 2014; 126(5–6):169–175.
Egan BM, Li J, Hutchison FN, Ferdinand KC. Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation. 2014; 130(19):1692–1699.
Tao Z, Shi A, Zhao J. Epidemiological perspectives of diabetes. Cell Biochem Biophys. 2015; 73(1):181–185.
O’Donnell CJ, Nabel EG. Cardiovascular genomics, personalized medicine, and the National Heart, Lung, and Blood Institute: part I: The beginning of an era. Circ Cardiovasc Genet. 2008; 1(1):51–57.
Desai JR, Vazquez-Benitez G, Xu Z, et al. Who must we target now to minimize future cardiovascular events and total mortality? Lessons From the SUPREME-DM Cohort Study. Circ Cardiovasc Qual Outcomes. 2015; in press.
Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev. 2002;(4):CD002785.
Hol A, Divrikli U, Elci L. Determination of cobalt, nickel and iron at trace level in natural water samples by in-column chelation-reversed phase high-performance liquid chromatography. Environ Monit Assess. 2012; 184(6):3469–3479.
Cario H, Janka-Schaub G, Janssen G, et al. Recent developments in iron chelation therapy. Klin Padiatr. 2007; 219(3):158–165.
Flora SJ, Flora G, Saxena G, Mishra M. Arsenic and lead induced free radical generation and their reversibility following chelation. Cell Mol Biol (Noisy-le-grand). 2007; 53(1):26–47.
Solenkova NV, Newman JD, Berger JS, et al. Metal pollutants and cardiovascular disease: mechanisms and consequences of exposure. Am Heart J. 2014; 168(6):812–822.
Wegmann K. Chelation therapy to treat lead toxicity in children. Minn Med. 1992; 75(11):25–27.
Sánchez-Fructuoso AI, Cano M, Arroyo M, et al. Lead mobilization during calcium disodium ethylenediaminetetraacetate chelation therapy in treatment of chronic lead poisoning. Am J Kidney Dis. 2002; 40(1):51–58.
Lamas GA, Goertz C, Boineau R, et al. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J. 2012; 163(1):7–12.
Escolar E, Lamas GA, Mark DB, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 2014; 7(1):15–24.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.